Researchers have been excited about Retatrutide , a innovative dual agonist showing promising outcomes in clinical trials for size reduction . It works by modulating two systems: GLP-1 and GIP, that , when stimulated, help control hunger and boost metabolism . Preliminary observations suggest substantial size loss and possible benefits for people s